Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Alkermes, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $390.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 15.38%. This compares to year-ago revenues of $399.13 million. The company has topped consensus revenue estimates two times over the last four quarters. This quarterly report represents an earnings surprise of +26.83%. A quarter a ...